nodes	percent_of_prediction	percent_of_DWPC	metapath
Irbesartan—AGTR1—dilated cardiomyopathy	0.702	1	CbGaD
Irbesartan—CYP2C9—cardial valve—dilated cardiomyopathy	0.0121	0.302	CbGeAlD
Irbesartan—CYP2C8—Spironolactone—dilated cardiomyopathy	0.0106	1	CbGbCtD
Irbesartan—Angiitis necrotising—Furosemide—dilated cardiomyopathy	0.0055	0.0395	CcSEcCtD
Irbesartan—Xanthopsia—Furosemide—dilated cardiomyopathy	0.0055	0.0395	CcSEcCtD
Irbesartan—Vasculitis necrotising—Furosemide—dilated cardiomyopathy	0.0048	0.0344	CcSEcCtD
Irbesartan—Tasosartan—AGTR2—dilated cardiomyopathy	0.00325	0.337	CrCbGaD
Irbesartan—EDNRA—cardiac ventricle—dilated cardiomyopathy	0.00308	0.0769	CbGeAlD
Irbesartan—EDNRA—myocardium—dilated cardiomyopathy	0.0029	0.0723	CbGeAlD
Irbesartan—Common cold—Lisinopril—dilated cardiomyopathy	0.00289	0.0207	CcSEcCtD
Irbesartan—JUN—cardiac ventricle—dilated cardiomyopathy	0.00281	0.0701	CbGeAlD
Irbesartan—JUN—myocardium—dilated cardiomyopathy	0.00264	0.066	CbGeAlD
Irbesartan—Gastric irritation—Furosemide—dilated cardiomyopathy	0.00259	0.0186	CcSEcCtD
Irbesartan—Diabetic—Lisinopril—dilated cardiomyopathy	0.00226	0.0162	CcSEcCtD
Irbesartan—AGTR1—cardiac ventricle—dilated cardiomyopathy	0.00212	0.0528	CbGeAlD
Irbesartan—EDNRA—heart—dilated cardiomyopathy	0.00202	0.0505	CbGeAlD
Irbesartan—AGTR1—myocardium—dilated cardiomyopathy	0.00199	0.0497	CbGeAlD
Irbesartan—Epigastric discomfort—Furosemide—dilated cardiomyopathy	0.00191	0.0137	CcSEcCtD
Irbesartan—Vasculitis—Spironolactone—dilated cardiomyopathy	0.00189	0.0136	CcSEcCtD
Irbesartan—Forasartan—AGTR1—dilated cardiomyopathy	0.00186	0.193	CrCbGaD
Irbesartan—JUN—heart—dilated cardiomyopathy	0.00185	0.046	CbGeAlD
Irbesartan—Hyperkalaemia—Spironolactone—dilated cardiomyopathy	0.00182	0.013	CcSEcCtD
Irbesartan—EDNRA—cardiac atrium—dilated cardiomyopathy	0.00173	0.0432	CbGeAlD
Irbesartan—JUN—cardiac atrium—dilated cardiomyopathy	0.00158	0.0394	CbGeAlD
Irbesartan—Bursitis—Lisinopril—dilated cardiomyopathy	0.00156	0.0112	CcSEcCtD
Irbesartan—Transient ischaemic attack—Lisinopril—dilated cardiomyopathy	0.00149	0.0107	CcSEcCtD
Irbesartan—Nephritis interstitial—Furosemide—dilated cardiomyopathy	0.00149	0.0107	CcSEcCtD
Irbesartan—AGTR1—heart—dilated cardiomyopathy	0.00139	0.0347	CbGeAlD
Irbesartan—Blindness—Lisinopril—dilated cardiomyopathy	0.00136	0.00978	CcSEcCtD
Irbesartan—Sleep disturbance—Lisinopril—dilated cardiomyopathy	0.00135	0.00966	CcSEcCtD
Irbesartan—Tubulointerstitial nephritis—Furosemide—dilated cardiomyopathy	0.00131	0.00942	CcSEcCtD
Irbesartan—Glycosuria—Furosemide—dilated cardiomyopathy	0.00124	0.0089	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Spironolactone—dilated cardiomyopathy	0.00121	0.00867	CcSEcCtD
Irbesartan—Cramp muscle—Spironolactone—dilated cardiomyopathy	0.00121	0.00867	CcSEcCtD
Irbesartan—AGTR1—cardiac atrium—dilated cardiomyopathy	0.00119	0.0297	CbGeAlD
Irbesartan—Jaundice cholestatic—Furosemide—dilated cardiomyopathy	0.00114	0.00821	CcSEcCtD
Irbesartan—Tasosartan—AGTR1—dilated cardiomyopathy	0.00113	0.117	CrCbGaD
Irbesartan—Heartburn—Lisinopril—dilated cardiomyopathy	0.0011	0.00786	CcSEcCtD
Irbesartan—Hyperuricaemia—Furosemide—dilated cardiomyopathy	0.00108	0.00778	CcSEcCtD
Irbesartan—Drug interaction—Furosemide—dilated cardiomyopathy	0.00108	0.00778	CcSEcCtD
Irbesartan—Gout—Furosemide—dilated cardiomyopathy	0.00108	0.00773	CcSEcCtD
Irbesartan—Vasculitis—Furosemide—dilated cardiomyopathy	0.00103	0.00739	CcSEcCtD
Irbesartan—Blood uric acid increased—Furosemide—dilated cardiomyopathy	0.00102	0.00735	CcSEcCtD
Irbesartan—Renal failure—Spironolactone—dilated cardiomyopathy	0.00102	0.00729	CcSEcCtD
Irbesartan—Valsartan—AGTR1—dilated cardiomyopathy	0.000976	0.101	CrCbGaD
Irbesartan—Agranulocytosis—Spironolactone—dilated cardiomyopathy	0.000965	0.00692	CcSEcCtD
Irbesartan—Olmesartan—AGTR1—dilated cardiomyopathy	0.000951	0.0986	CrCbGaD
Irbesartan—Aplastic anaemia—Furosemide—dilated cardiomyopathy	0.000944	0.00677	CcSEcCtD
Irbesartan—Lightheadedness—Furosemide—dilated cardiomyopathy	0.0009	0.00645	CcSEcCtD
Irbesartan—PTGS1—myocardium—dilated cardiomyopathy	0.000875	0.0218	CbGeAlD
Irbesartan—Proteinuria—Lisinopril—dilated cardiomyopathy	0.000859	0.00616	CcSEcCtD
Irbesartan—Jaundice cholestatic—Lisinopril—dilated cardiomyopathy	0.000859	0.00616	CcSEcCtD
Irbesartan—Protein urine present—Lisinopril—dilated cardiomyopathy	0.000847	0.00607	CcSEcCtD
Irbesartan—Diabetes mellitus—Furosemide—dilated cardiomyopathy	0.000839	0.00602	CcSEcCtD
Irbesartan—Photosensitivity—Furosemide—dilated cardiomyopathy	0.000831	0.00596	CcSEcCtD
Irbesartan—Swelling—Furosemide—dilated cardiomyopathy	0.000827	0.00594	CcSEcCtD
Irbesartan—Drug interaction—Lisinopril—dilated cardiomyopathy	0.000813	0.00583	CcSEcCtD
Irbesartan—Haemolytic anaemia—Furosemide—dilated cardiomyopathy	0.000808	0.0058	CcSEcCtD
Irbesartan—Gout—Lisinopril—dilated cardiomyopathy	0.000808	0.0058	CcSEcCtD
Irbesartan—Muscle spasms—Spironolactone—dilated cardiomyopathy	0.000777	0.00557	CcSEcCtD
Irbesartan—Vasculitis—Lisinopril—dilated cardiomyopathy	0.000773	0.00555	CcSEcCtD
Irbesartan—Musculoskeletal pain—Lisinopril—dilated cardiomyopathy	0.000764	0.00548	CcSEcCtD
Irbesartan—Ill-defined disorder—Spironolactone—dilated cardiomyopathy	0.00075	0.00538	CcSEcCtD
Irbesartan—Hyperkalaemia—Lisinopril—dilated cardiomyopathy	0.000741	0.00532	CcSEcCtD
Irbesartan—Candesartan—AGTR1—dilated cardiomyopathy	0.00074	0.0766	CrCbGaD
Irbesartan—Hyponatraemia—Furosemide—dilated cardiomyopathy	0.000733	0.00526	CcSEcCtD
Irbesartan—Wheezing—Lisinopril—dilated cardiomyopathy	0.000733	0.00526	CcSEcCtD
Irbesartan—Malaise—Spironolactone—dilated cardiomyopathy	0.000729	0.00523	CcSEcCtD
Irbesartan—Leukopenia—Spironolactone—dilated cardiomyopathy	0.000723	0.00519	CcSEcCtD
Irbesartan—Blood urea increased—Lisinopril—dilated cardiomyopathy	0.000712	0.00511	CcSEcCtD
Irbesartan—Discomfort—Spironolactone—dilated cardiomyopathy	0.00068	0.00488	CcSEcCtD
Irbesartan—Lightheadedness—Lisinopril—dilated cardiomyopathy	0.000675	0.00484	CcSEcCtD
Irbesartan—Pulmonary oedema—Lisinopril—dilated cardiomyopathy	0.000671	0.00482	CcSEcCtD
Irbesartan—CYP2C9—heart—dilated cardiomyopathy	0.000669	0.0167	CbGeAlD
Irbesartan—Orthostatic hypotension—Furosemide—dilated cardiomyopathy	0.000667	0.00478	CcSEcCtD
Irbesartan—Hypokalaemia—Furosemide—dilated cardiomyopathy	0.000664	0.00477	CcSEcCtD
Irbesartan—Anaphylactic shock—Spironolactone—dilated cardiomyopathy	0.000659	0.00473	CcSEcCtD
Irbesartan—Cramp muscle—Furosemide—dilated cardiomyopathy	0.000657	0.00472	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Furosemide—dilated cardiomyopathy	0.000657	0.00472	CcSEcCtD
Irbesartan—Thrombocytopenia—Spironolactone—dilated cardiomyopathy	0.000646	0.00463	CcSEcCtD
Irbesartan—Muscular weakness—Furosemide—dilated cardiomyopathy	0.000644	0.00462	CcSEcCtD
Irbesartan—Abdominal distension—Furosemide—dilated cardiomyopathy	0.000635	0.00456	CcSEcCtD
Irbesartan—Sleep disorder—Lisinopril—dilated cardiomyopathy	0.000633	0.00454	CcSEcCtD
Irbesartan—Diabetes mellitus—Lisinopril—dilated cardiomyopathy	0.00063	0.00452	CcSEcCtD
Irbesartan—Hepatic function abnormal—Lisinopril—dilated cardiomyopathy	0.000627	0.0045	CcSEcCtD
Irbesartan—Photosensitivity—Lisinopril—dilated cardiomyopathy	0.000624	0.00447	CcSEcCtD
Irbesartan—Pancreatitis—Furosemide—dilated cardiomyopathy	0.000618	0.00444	CcSEcCtD
Irbesartan—Gastroenteritis—Lisinopril—dilated cardiomyopathy	0.000618	0.00443	CcSEcCtD
Irbesartan—PTGS1—heart—dilated cardiomyopathy	0.000611	0.0152	CbGeAlD
Irbesartan—Haemolytic anaemia—Lisinopril—dilated cardiomyopathy	0.000607	0.00435	CcSEcCtD
Irbesartan—Injury—Lisinopril—dilated cardiomyopathy	0.000596	0.00427	CcSEcCtD
Irbesartan—Somnolence—Spironolactone—dilated cardiomyopathy	0.000586	0.00421	CcSEcCtD
Irbesartan—Photosensitivity reaction—Furosemide—dilated cardiomyopathy	0.000576	0.00413	CcSEcCtD
Irbesartan—Renal impairment—Lisinopril—dilated cardiomyopathy	0.000575	0.00413	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Spironolactone—dilated cardiomyopathy	0.000569	0.00408	CcSEcCtD
Irbesartan—Hyperglycaemia—Furosemide—dilated cardiomyopathy	0.000569	0.00408	CcSEcCtD
Irbesartan—Arthritis—Lisinopril—dilated cardiomyopathy	0.000563	0.00404	CcSEcCtD
Irbesartan—Cerebrovascular accident—Lisinopril—dilated cardiomyopathy	0.000559	0.00401	CcSEcCtD
Irbesartan—Renal failure—Furosemide—dilated cardiomyopathy	0.000553	0.00397	CcSEcCtD
Irbesartan—Hyponatraemia—Lisinopril—dilated cardiomyopathy	0.00055	0.00394	CcSEcCtD
Irbesartan—Feeling abnormal—Spironolactone—dilated cardiomyopathy	0.000543	0.0039	CcSEcCtD
Irbesartan—Hepatobiliary disease—Furosemide—dilated cardiomyopathy	0.000532	0.00382	CcSEcCtD
Irbesartan—Face oedema—Lisinopril—dilated cardiomyopathy	0.000529	0.00379	CcSEcCtD
Irbesartan—Agranulocytosis—Furosemide—dilated cardiomyopathy	0.000525	0.00377	CcSEcCtD
Irbesartan—Urticaria—Spironolactone—dilated cardiomyopathy	0.000524	0.00376	CcSEcCtD
Irbesartan—PTGS1—cardiac atrium—dilated cardiomyopathy	0.000522	0.013	CbGeAlD
Irbesartan—Body temperature increased—Spironolactone—dilated cardiomyopathy	0.000521	0.00374	CcSEcCtD
Irbesartan—Orthostatic hypotension—Lisinopril—dilated cardiomyopathy	0.0005	0.00359	CcSEcCtD
Irbesartan—Urinary tract disorder—Furosemide—dilated cardiomyopathy	0.000499	0.00358	CcSEcCtD
Irbesartan—Urethral disorder—Furosemide—dilated cardiomyopathy	0.000495	0.00355	CcSEcCtD
Irbesartan—Breast disorder—Lisinopril—dilated cardiomyopathy	0.000495	0.00355	CcSEcCtD
Irbesartan—Toxic epidermal necrolysis—Lisinopril—dilated cardiomyopathy	0.000493	0.00354	CcSEcCtD
Irbesartan—Cramp muscle—Lisinopril—dilated cardiomyopathy	0.000493	0.00354	CcSEcCtD
Irbesartan—Nasopharyngitis—Lisinopril—dilated cardiomyopathy	0.00049	0.00351	CcSEcCtD
Irbesartan—Visual impairment—Furosemide—dilated cardiomyopathy	0.000487	0.00349	CcSEcCtD
Irbesartan—Hypersensitivity—Spironolactone—dilated cardiomyopathy	0.000486	0.00349	CcSEcCtD
Irbesartan—Losartan—AGTR1—dilated cardiomyopathy	0.000477	0.0494	CrCbGaD
Irbesartan—Asthma—Lisinopril—dilated cardiomyopathy	0.000473	0.0034	CcSEcCtD
Irbesartan—Influenza—Lisinopril—dilated cardiomyopathy	0.000473	0.0034	CcSEcCtD
Irbesartan—Tinnitus—Furosemide—dilated cardiomyopathy	0.000471	0.00338	CcSEcCtD
Irbesartan—Pruritus—Spironolactone—dilated cardiomyopathy	0.000466	0.00335	CcSEcCtD
Irbesartan—Pancreatitis—Lisinopril—dilated cardiomyopathy	0.000464	0.00333	CcSEcCtD
Irbesartan—Angina pectoris—Lisinopril—dilated cardiomyopathy	0.000461	0.00331	CcSEcCtD
Irbesartan—Angiopathy—Furosemide—dilated cardiomyopathy	0.000458	0.00329	CcSEcCtD
Irbesartan—Immune system disorder—Furosemide—dilated cardiomyopathy	0.000456	0.00327	CcSEcCtD
Irbesartan—Diarrhoea—Spironolactone—dilated cardiomyopathy	0.000451	0.00324	CcSEcCtD
Irbesartan—Arrhythmia—Furosemide—dilated cardiomyopathy	0.000451	0.00324	CcSEcCtD
Irbesartan—Neutropenia—Lisinopril—dilated cardiomyopathy	0.000443	0.00318	CcSEcCtD
Irbesartan—Upper respiratory tract infection—Lisinopril—dilated cardiomyopathy	0.00044	0.00316	CcSEcCtD
Irbesartan—Malnutrition—Furosemide—dilated cardiomyopathy	0.00044	0.00315	CcSEcCtD
Irbesartan—Erythema—Furosemide—dilated cardiomyopathy	0.00044	0.00315	CcSEcCtD
Irbesartan—Dizziness—Spironolactone—dilated cardiomyopathy	0.000436	0.00313	CcSEcCtD
Irbesartan—Flatulence—Furosemide—dilated cardiomyopathy	0.000433	0.00311	CcSEcCtD
Irbesartan—Photosensitivity reaction—Lisinopril—dilated cardiomyopathy	0.000432	0.0031	CcSEcCtD
Irbesartan—Weight increased—Lisinopril—dilated cardiomyopathy	0.000431	0.00309	CcSEcCtD
Irbesartan—Dysgeusia—Furosemide—dilated cardiomyopathy	0.00043	0.00309	CcSEcCtD
Irbesartan—Hyperglycaemia—Lisinopril—dilated cardiomyopathy	0.000427	0.00306	CcSEcCtD
Irbesartan—Pneumonia—Lisinopril—dilated cardiomyopathy	0.000424	0.00305	CcSEcCtD
Irbesartan—Muscle spasms—Furosemide—dilated cardiomyopathy	0.000423	0.00303	CcSEcCtD
Irbesartan—Vomiting—Spironolactone—dilated cardiomyopathy	0.000419	0.00301	CcSEcCtD
Irbesartan—Acute coronary syndrome—Lisinopril—dilated cardiomyopathy	0.000416	0.00298	CcSEcCtD
Irbesartan—Rash—Spironolactone—dilated cardiomyopathy	0.000416	0.00298	CcSEcCtD
Irbesartan—Dermatitis—Spironolactone—dilated cardiomyopathy	0.000415	0.00298	CcSEcCtD
Irbesartan—Renal failure—Lisinopril—dilated cardiomyopathy	0.000415	0.00298	CcSEcCtD
Irbesartan—Vision blurred—Furosemide—dilated cardiomyopathy	0.000414	0.00297	CcSEcCtD
Irbesartan—Myocardial infarction—Lisinopril—dilated cardiomyopathy	0.000414	0.00297	CcSEcCtD
Irbesartan—Headache—Spironolactone—dilated cardiomyopathy	0.000413	0.00296	CcSEcCtD
Irbesartan—Jaundice—Lisinopril—dilated cardiomyopathy	0.000411	0.00295	CcSEcCtD
Irbesartan—Urinary tract infection—Lisinopril—dilated cardiomyopathy	0.00041	0.00294	CcSEcCtD
Irbesartan—Anaemia—Furosemide—dilated cardiomyopathy	0.000406	0.00291	CcSEcCtD
Irbesartan—Agitation—Furosemide—dilated cardiomyopathy	0.000404	0.0029	CcSEcCtD
Irbesartan—Hepatobiliary disease—Lisinopril—dilated cardiomyopathy	0.000399	0.00286	CcSEcCtD
Irbesartan—Epistaxis—Lisinopril—dilated cardiomyopathy	0.000398	0.00286	CcSEcCtD
Irbesartan—Vertigo—Furosemide—dilated cardiomyopathy	0.000395	0.00283	CcSEcCtD
Irbesartan—Agranulocytosis—Lisinopril—dilated cardiomyopathy	0.000394	0.00283	CcSEcCtD
Irbesartan—Leukopenia—Furosemide—dilated cardiomyopathy	0.000393	0.00282	CcSEcCtD
Irbesartan—Nausea—Spironolactone—dilated cardiomyopathy	0.000392	0.00281	CcSEcCtD
Irbesartan—Bradycardia—Lisinopril—dilated cardiomyopathy	0.000386	0.00277	CcSEcCtD
Irbesartan—Rhinitis—Lisinopril—dilated cardiomyopathy	0.00038	0.00272	CcSEcCtD
Irbesartan—Hepatitis—Lisinopril—dilated cardiomyopathy	0.000379	0.00272	CcSEcCtD
Irbesartan—Pharyngitis—Lisinopril—dilated cardiomyopathy	0.000376	0.0027	CcSEcCtD
Irbesartan—Urinary tract disorder—Lisinopril—dilated cardiomyopathy	0.000374	0.00268	CcSEcCtD
Irbesartan—Oedema peripheral—Lisinopril—dilated cardiomyopathy	0.000373	0.00268	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Furosemide—dilated cardiomyopathy	0.000372	0.00267	CcSEcCtD
Irbesartan—Urethral disorder—Lisinopril—dilated cardiomyopathy	0.000371	0.00266	CcSEcCtD
Irbesartan—Dry mouth—Furosemide—dilated cardiomyopathy	0.000366	0.00263	CcSEcCtD
Irbesartan—Anaphylactic shock—Furosemide—dilated cardiomyopathy	0.000359	0.00257	CcSEcCtD
Irbesartan—Tinnitus—Lisinopril—dilated cardiomyopathy	0.000353	0.00253	CcSEcCtD
Irbesartan—Shock—Furosemide—dilated cardiomyopathy	0.000353	0.00253	CcSEcCtD
Irbesartan—Nervous system disorder—Furosemide—dilated cardiomyopathy	0.000352	0.00252	CcSEcCtD
Irbesartan—Flushing—Lisinopril—dilated cardiomyopathy	0.000352	0.00252	CcSEcCtD
Irbesartan—Thrombocytopenia—Furosemide—dilated cardiomyopathy	0.000351	0.00252	CcSEcCtD
Irbesartan—Skin disorder—Furosemide—dilated cardiomyopathy	0.000348	0.0025	CcSEcCtD
Irbesartan—Hyperhidrosis—Furosemide—dilated cardiomyopathy	0.000347	0.00249	CcSEcCtD
Irbesartan—Angiopathy—Lisinopril—dilated cardiomyopathy	0.000344	0.00247	CcSEcCtD
Irbesartan—Anorexia—Furosemide—dilated cardiomyopathy	0.000342	0.00245	CcSEcCtD
Irbesartan—Mediastinal disorder—Lisinopril—dilated cardiomyopathy	0.000341	0.00245	CcSEcCtD
Irbesartan—Chills—Lisinopril—dilated cardiomyopathy	0.00034	0.00244	CcSEcCtD
Irbesartan—Arrhythmia—Lisinopril—dilated cardiomyopathy	0.000338	0.00243	CcSEcCtD
Irbesartan—Hypotension—Furosemide—dilated cardiomyopathy	0.000335	0.0024	CcSEcCtD
Irbesartan—Erythema—Lisinopril—dilated cardiomyopathy	0.00033	0.00237	CcSEcCtD
Irbesartan—Malnutrition—Lisinopril—dilated cardiomyopathy	0.00033	0.00237	CcSEcCtD
Irbesartan—Flatulence—Lisinopril—dilated cardiomyopathy	0.000325	0.00233	CcSEcCtD
Irbesartan—Tension—Lisinopril—dilated cardiomyopathy	0.000324	0.00232	CcSEcCtD
Irbesartan—Dysgeusia—Lisinopril—dilated cardiomyopathy	0.000323	0.00232	CcSEcCtD
Irbesartan—Paraesthesia—Furosemide—dilated cardiomyopathy	0.000322	0.00231	CcSEcCtD
Irbesartan—Nervousness—Lisinopril—dilated cardiomyopathy	0.00032	0.0023	CcSEcCtD
Irbesartan—Somnolence—Furosemide—dilated cardiomyopathy	0.000319	0.00229	CcSEcCtD
Irbesartan—Muscle spasms—Lisinopril—dilated cardiomyopathy	0.000317	0.00227	CcSEcCtD
Irbesartan—Decreased appetite—Furosemide—dilated cardiomyopathy	0.000312	0.00224	CcSEcCtD
Irbesartan—Vision blurred—Lisinopril—dilated cardiomyopathy	0.000311	0.00223	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Furosemide—dilated cardiomyopathy	0.00031	0.00222	CcSEcCtD
Irbesartan—Fatigue—Furosemide—dilated cardiomyopathy	0.000309	0.00222	CcSEcCtD
Irbesartan—Tremor—Lisinopril—dilated cardiomyopathy	0.000309	0.00222	CcSEcCtD
Irbesartan—Pain—Furosemide—dilated cardiomyopathy	0.000307	0.0022	CcSEcCtD
Irbesartan—Constipation—Furosemide—dilated cardiomyopathy	0.000307	0.0022	CcSEcCtD
Irbesartan—Ill-defined disorder—Lisinopril—dilated cardiomyopathy	0.000306	0.0022	CcSEcCtD
Irbesartan—Anaemia—Lisinopril—dilated cardiomyopathy	0.000305	0.00219	CcSEcCtD
Irbesartan—Angioedema—Lisinopril—dilated cardiomyopathy	0.000301	0.00216	CcSEcCtD
Irbesartan—Malaise—Lisinopril—dilated cardiomyopathy	0.000297	0.00213	CcSEcCtD
Irbesartan—Vertigo—Lisinopril—dilated cardiomyopathy	0.000296	0.00213	CcSEcCtD
Irbesartan—Syncope—Lisinopril—dilated cardiomyopathy	0.000296	0.00212	CcSEcCtD
Irbesartan—Feeling abnormal—Furosemide—dilated cardiomyopathy	0.000296	0.00212	CcSEcCtD
Irbesartan—Leukopenia—Lisinopril—dilated cardiomyopathy	0.000295	0.00212	CcSEcCtD
Irbesartan—Gastrointestinal pain—Furosemide—dilated cardiomyopathy	0.000293	0.0021	CcSEcCtD
Irbesartan—Loss of consciousness—Lisinopril—dilated cardiomyopathy	0.00029	0.00208	CcSEcCtD
Irbesartan—Cough—Lisinopril—dilated cardiomyopathy	0.000288	0.00206	CcSEcCtD
Irbesartan—Urticaria—Furosemide—dilated cardiomyopathy	0.000285	0.00204	CcSEcCtD
Irbesartan—Abdominal pain—Furosemide—dilated cardiomyopathy	0.000284	0.00203	CcSEcCtD
Irbesartan—Body temperature increased—Furosemide—dilated cardiomyopathy	0.000284	0.00203	CcSEcCtD
Irbesartan—Chest pain—Lisinopril—dilated cardiomyopathy	0.000281	0.00201	CcSEcCtD
Irbesartan—Myalgia—Lisinopril—dilated cardiomyopathy	0.000281	0.00201	CcSEcCtD
Irbesartan—Arthralgia—Lisinopril—dilated cardiomyopathy	0.000281	0.00201	CcSEcCtD
Irbesartan—Anxiety—Lisinopril—dilated cardiomyopathy	0.00028	0.00201	CcSEcCtD
Irbesartan—Unspecified disorder of skin and subcutaneous tissue—Lisinopril—dilated cardiomyopathy	0.000279	0.002	CcSEcCtD
Irbesartan—Discomfort—Lisinopril—dilated cardiomyopathy	0.000277	0.00199	CcSEcCtD
Irbesartan—Losartan—ACE—dilated cardiomyopathy	0.000276	0.0285	CrCbGaD
Irbesartan—Dry mouth—Lisinopril—dilated cardiomyopathy	0.000275	0.00197	CcSEcCtD
Irbesartan—Anaphylactic shock—Lisinopril—dilated cardiomyopathy	0.000269	0.00193	CcSEcCtD
Irbesartan—Oedema—Lisinopril—dilated cardiomyopathy	0.000269	0.00193	CcSEcCtD
Irbesartan—Infection—Lisinopril—dilated cardiomyopathy	0.000267	0.00192	CcSEcCtD
Irbesartan—Shock—Lisinopril—dilated cardiomyopathy	0.000265	0.0019	CcSEcCtD
Irbesartan—Hypersensitivity—Furosemide—dilated cardiomyopathy	0.000264	0.0019	CcSEcCtD
Irbesartan—Thrombocytopenia—Lisinopril—dilated cardiomyopathy	0.000264	0.00189	CcSEcCtD
Irbesartan—Tachycardia—Lisinopril—dilated cardiomyopathy	0.000263	0.00188	CcSEcCtD
Irbesartan—Skin disorder—Lisinopril—dilated cardiomyopathy	0.000261	0.00188	CcSEcCtD
Irbesartan—Hyperhidrosis—Lisinopril—dilated cardiomyopathy	0.00026	0.00187	CcSEcCtD
Irbesartan—Asthenia—Furosemide—dilated cardiomyopathy	0.000257	0.00185	CcSEcCtD
Irbesartan—Anorexia—Lisinopril—dilated cardiomyopathy	0.000257	0.00184	CcSEcCtD
Irbesartan—Pruritus—Furosemide—dilated cardiomyopathy	0.000254	0.00182	CcSEcCtD
Irbesartan—Hypotension—Lisinopril—dilated cardiomyopathy	0.000251	0.0018	CcSEcCtD
Irbesartan—Diarrhoea—Furosemide—dilated cardiomyopathy	0.000245	0.00176	CcSEcCtD
Irbesartan—Musculoskeletal discomfort—Lisinopril—dilated cardiomyopathy	0.000245	0.00176	CcSEcCtD
Irbesartan—Paraesthesia—Lisinopril—dilated cardiomyopathy	0.000242	0.00173	CcSEcCtD
Irbesartan—Dyspnoea—Lisinopril—dilated cardiomyopathy	0.00024	0.00172	CcSEcCtD
Irbesartan—Somnolence—Lisinopril—dilated cardiomyopathy	0.000239	0.00172	CcSEcCtD
Irbesartan—Dizziness—Furosemide—dilated cardiomyopathy	0.000237	0.0017	CcSEcCtD
Irbesartan—Dyspepsia—Lisinopril—dilated cardiomyopathy	0.000237	0.0017	CcSEcCtD
Irbesartan—Decreased appetite—Lisinopril—dilated cardiomyopathy	0.000234	0.00168	CcSEcCtD
Irbesartan—Gastrointestinal disorder—Lisinopril—dilated cardiomyopathy	0.000232	0.00167	CcSEcCtD
Irbesartan—Fatigue—Lisinopril—dilated cardiomyopathy	0.000232	0.00166	CcSEcCtD
Irbesartan—Pain—Lisinopril—dilated cardiomyopathy	0.00023	0.00165	CcSEcCtD
Irbesartan—Constipation—Lisinopril—dilated cardiomyopathy	0.00023	0.00165	CcSEcCtD
Irbesartan—Vomiting—Furosemide—dilated cardiomyopathy	0.000228	0.00164	CcSEcCtD
Irbesartan—Rash—Furosemide—dilated cardiomyopathy	0.000226	0.00162	CcSEcCtD
Irbesartan—Dermatitis—Furosemide—dilated cardiomyopathy	0.000226	0.00162	CcSEcCtD
Irbesartan—Headache—Furosemide—dilated cardiomyopathy	0.000225	0.00161	CcSEcCtD
Irbesartan—Feeling abnormal—Lisinopril—dilated cardiomyopathy	0.000222	0.00159	CcSEcCtD
Irbesartan—Gastrointestinal pain—Lisinopril—dilated cardiomyopathy	0.00022	0.00158	CcSEcCtD
Irbesartan—Urticaria—Lisinopril—dilated cardiomyopathy	0.000214	0.00153	CcSEcCtD
Irbesartan—Nausea—Furosemide—dilated cardiomyopathy	0.000213	0.00153	CcSEcCtD
Irbesartan—Body temperature increased—Lisinopril—dilated cardiomyopathy	0.000213	0.00153	CcSEcCtD
Irbesartan—Abdominal pain—Lisinopril—dilated cardiomyopathy	0.000213	0.00153	CcSEcCtD
Irbesartan—Hypersensitivity—Lisinopril—dilated cardiomyopathy	0.000198	0.00142	CcSEcCtD
Irbesartan—Asthenia—Lisinopril—dilated cardiomyopathy	0.000193	0.00139	CcSEcCtD
Irbesartan—Pruritus—Lisinopril—dilated cardiomyopathy	0.00019	0.00137	CcSEcCtD
Irbesartan—Diarrhoea—Lisinopril—dilated cardiomyopathy	0.000184	0.00132	CcSEcCtD
Irbesartan—JUN—Toll Like Receptor 4 (TLR4) Cascade—CD36—dilated cardiomyopathy	0.000179	0.00182	CbGpPWpGaD
Irbesartan—Dizziness—Lisinopril—dilated cardiomyopathy	0.000178	0.00128	CcSEcCtD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—GJA1—dilated cardiomyopathy	0.000176	0.00179	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000174	0.00177	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—SOD2—dilated cardiomyopathy	0.000174	0.00177	CbGpPWpGaD
Irbesartan—JUN—CDC42 signaling events—RAF1—dilated cardiomyopathy	0.000174	0.00177	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000174	0.00177	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—CXCR3—dilated cardiomyopathy	0.000174	0.00177	CbGpPWpGaD
Irbesartan—Vomiting—Lisinopril—dilated cardiomyopathy	0.000171	0.00123	CcSEcCtD
Irbesartan—JUN—FAS pathway and Stress induction of HSP regulation—TNF—dilated cardiomyopathy	0.000171	0.00174	CbGpPWpGaD
Irbesartan—JUN—TWEAK Signaling Pathway—TNF—dilated cardiomyopathy	0.000171	0.00174	CbGpPWpGaD
Irbesartan—Rash—Lisinopril—dilated cardiomyopathy	0.00017	0.00122	CcSEcCtD
Irbesartan—Dermatitis—Lisinopril—dilated cardiomyopathy	0.00017	0.00122	CcSEcCtD
Irbesartan—EDNRA—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000169	0.00172	CbGpPWpGaD
Irbesartan—CYP2C8—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000169	0.00172	CbGpPWpGaD
Irbesartan—Headache—Lisinopril—dilated cardiomyopathy	0.000169	0.00121	CcSEcCtD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRB1—dilated cardiomyopathy	0.000169	0.00171	CbGpPWpGaD
Irbesartan—JUN—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	0.000167	0.0017	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—GPX1—dilated cardiomyopathy	0.000166	0.00169	CbGpPWpGaD
Irbesartan—JUN—PDGFR-beta signaling pathway—RAC1—dilated cardiomyopathy	0.000165	0.00168	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—GPX1—dilated cardiomyopathy	0.000164	0.00167	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000164	0.00166	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—RPS6KB1—dilated cardiomyopathy	0.000163	0.00166	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000162	0.00164	CbGpPWpGaD
Irbesartan—Nausea—Lisinopril—dilated cardiomyopathy	0.00016	0.00115	CcSEcCtD
Irbesartan—AGTR1—GPCRs, Class A Rhodopsin-like—ADRB2—dilated cardiomyopathy	0.000159	0.00162	CbGpPWpGaD
Irbesartan—JUN—Toll-Like Receptors Cascades—CD36—dilated cardiomyopathy	0.000159	0.00162	CbGpPWpGaD
Irbesartan—JUN—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	0.000159	0.00162	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—RAC1—dilated cardiomyopathy	0.000158	0.00161	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—IL10—dilated cardiomyopathy	0.000157	0.0016	CbGpPWpGaD
Irbesartan—JUN—Signaling events mediated by Hepatocyte Growth Factor Receptor (c-Met)—RAF1—dilated cardiomyopathy	0.000156	0.00159	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—FAS—dilated cardiomyopathy	0.000154	0.00156	CbGpPWpGaD
Irbesartan—AGTR1—G alpha (q) signalling events—AGT—dilated cardiomyopathy	0.000153	0.00156	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	0.000152	0.00155	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—RAC1—dilated cardiomyopathy	0.000152	0.00154	CbGpPWpGaD
Irbesartan—AGTR1—Peptide ligand-binding receptors—AGT—dilated cardiomyopathy	0.000151	0.00154	CbGpPWpGaD
Irbesartan—JUN—Insulin Signaling—RPS6KB1—dilated cardiomyopathy	0.00015	0.00153	CbGpPWpGaD
Irbesartan—JUN—Calcineurin-regulated NFAT-dependent transcription in lymphocytes—TNF—dilated cardiomyopathy	0.000149	0.00151	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—RPS6KB1—dilated cardiomyopathy	0.000148	0.00151	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—RAC1—dilated cardiomyopathy	0.000147	0.0015	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—ITGB1—dilated cardiomyopathy	0.000147	0.00149	CbGpPWpGaD
Irbesartan—JUN—ErbB Signaling Pathway—EGFR—dilated cardiomyopathy	0.000147	0.00149	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—CXCL2—dilated cardiomyopathy	0.000143	0.00145	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—AGTR2—dilated cardiomyopathy	0.000143	0.00145	CbGpPWpGaD
Irbesartan—JUN—TCR Signaling Pathway—RAF1—dilated cardiomyopathy	0.000142	0.00145	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—RAC1—dilated cardiomyopathy	0.000142	0.00144	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Receptor Signaling—TNF—dilated cardiomyopathy	0.00014	0.00142	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—RAF1—dilated cardiomyopathy	0.00014	0.00142	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—AGTR1—dilated cardiomyopathy	0.00014	0.00142	CbGpPWpGaD
Irbesartan—AGTR1—Allograft Rejection—TNF—dilated cardiomyopathy	0.000138	0.0014	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—FASLG—dilated cardiomyopathy	0.000138	0.0014	CbGpPWpGaD
Irbesartan—CYP2C9—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000137	0.0014	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—AGT—dilated cardiomyopathy	0.000137	0.00139	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—ADRB2—dilated cardiomyopathy	0.000137	0.00139	CbGpPWpGaD
Irbesartan—JUN—Insulin Signaling—RAC1—dilated cardiomyopathy	0.000136	0.00138	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—RAC1—dilated cardiomyopathy	0.000134	0.00136	CbGpPWpGaD
Irbesartan—JUN—B Cell Receptor Signaling Pathway—RAF1—dilated cardiomyopathy	0.000134	0.00136	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—FAS—dilated cardiomyopathy	0.000133	0.00135	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—CXCR3—dilated cardiomyopathy	0.000133	0.00135	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000133	0.00135	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—RAC1—dilated cardiomyopathy	0.00013	0.00133	CbGpPWpGaD
Irbesartan—EDNRA—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000129	0.00131	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—ADRB1—dilated cardiomyopathy	0.000128	0.00131	CbGpPWpGaD
Irbesartan—JUN—LPA receptor mediated events—EGFR—dilated cardiomyopathy	0.000128	0.0013	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—ANKRD1—dilated cardiomyopathy	0.000128	0.0013	CbGpPWpGaD
Irbesartan—JUN—Senescence and Autophagy in Cancer—RAF1—dilated cardiomyopathy	0.000126	0.00128	CbGpPWpGaD
Irbesartan—JUN—ErbB1 downstream signaling—RAF1—dilated cardiomyopathy	0.000126	0.00128	CbGpPWpGaD
Irbesartan—JUN—AGE/RAGE pathway—EGFR—dilated cardiomyopathy	0.000125	0.00127	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—RAC1—dilated cardiomyopathy	0.000125	0.00127	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—FASLG—dilated cardiomyopathy	0.000124	0.00127	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—CD36—dilated cardiomyopathy	0.000122	0.00124	CbGpPWpGaD
Irbesartan—JUN—Regulation of Telomerase—EGFR—dilated cardiomyopathy	0.000122	0.00124	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	0.000121	0.00123	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—TAZ—dilated cardiomyopathy	0.00012	0.00122	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—FAS—dilated cardiomyopathy	0.00012	0.00122	CbGpPWpGaD
Irbesartan—JUN—Downstream signaling in naïve CD8+ T cells—TNF—dilated cardiomyopathy	0.000119	0.00121	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—RAC1—dilated cardiomyopathy	0.000118	0.0012	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—RAC1—dilated cardiomyopathy	0.000118	0.0012	CbGpPWpGaD
Irbesartan—CYP1A2—Arachidonic acid metabolism—GPX1—dilated cardiomyopathy	0.000117	0.00119	CbGpPWpGaD
Irbesartan—JUN—Circadian rythm related genes—FAS—dilated cardiomyopathy	0.000115	0.00117	CbGpPWpGaD
Irbesartan—JUN—PDGFR-beta signaling pathway—RAF1—dilated cardiomyopathy	0.000109	0.00111	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—SDHA—dilated cardiomyopathy	0.000109	0.00111	CbGpPWpGaD
Irbesartan—JUN—TGF-beta Signaling Pathway—RAF1—dilated cardiomyopathy	0.000105	0.00107	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	0.000104	0.00106	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—ADRB2—dilated cardiomyopathy	0.000104	0.00106	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—SOD2—dilated cardiomyopathy	0.000104	0.00105	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	0.000103	0.00104	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	0.000103	0.00104	CbGpPWpGaD
Irbesartan—AGTR1—Class A/1 (Rhodopsin-like receptors)—AGT—dilated cardiomyopathy	0.000101	0.00103	CbGpPWpGaD
Irbesartan—JUN—Cellular responses to stress—GPX1—dilated cardiomyopathy	9.89e-05	0.00101	CbGpPWpGaD
Irbesartan—JUN—Androgen receptor signaling pathway—EGFR—dilated cardiomyopathy	9.85e-05	0.001	CbGpPWpGaD
Irbesartan—EDNRA—GPCR ligand binding—AGT—dilated cardiomyopathy	9.83e-05	0.001	CbGpPWpGaD
Irbesartan—JUN—Apoptosis—TNF—dilated cardiomyopathy	9.83e-05	0.000999	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	9.82e-05	0.000999	CbGpPWpGaD
Irbesartan—JUN—BDNF signaling pathway—RAF1—dilated cardiomyopathy	9.78e-05	0.000994	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	9.55e-05	0.000971	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—RAF1—dilated cardiomyopathy	9.49e-05	0.000966	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—AGTR2—dilated cardiomyopathy	9.32e-05	0.000948	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—CXCL2—dilated cardiomyopathy	9.32e-05	0.000948	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	9.24e-05	0.00094	CbGpPWpGaD
Irbesartan—JUN—TNF alpha Signaling Pathway—TNF—dilated cardiomyopathy	9.14e-05	0.000929	CbGpPWpGaD
Irbesartan—JUN—Insulin Signaling—RAF1—dilated cardiomyopathy	8.99e-05	0.000914	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—RAF1—dilated cardiomyopathy	8.9e-05	0.000905	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—CXCR3—dilated cardiomyopathy	8.67e-05	0.000882	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—RAF1—dilated cardiomyopathy	8.64e-05	0.000879	CbGpPWpGaD
Irbesartan—JUN—ErbB1 downstream signaling—EGFR—dilated cardiomyopathy	8.63e-05	0.000878	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	8.5e-05	0.000865	CbGpPWpGaD
Irbesartan—JUN—Toll-like Receptor Signaling Pathway—TNF—dilated cardiomyopathy	8.41e-05	0.000856	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—ADRB1—dilated cardiomyopathy	8.39e-05	0.000854	CbGpPWpGaD
Irbesartan—EDNRA—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	8.3e-05	0.000844	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—RAF1—dilated cardiomyopathy	8.29e-05	0.000843	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—CXCL2—dilated cardiomyopathy	8.06e-05	0.000819	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—AGTR2—dilated cardiomyopathy	8.06e-05	0.000819	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	7.99e-05	0.000813	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—AGTR1—dilated cardiomyopathy	7.9e-05	0.000803	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—RAF1—dilated cardiomyopathy	7.83e-05	0.000796	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—RAF1—dilated cardiomyopathy	7.8e-05	0.000793	CbGpPWpGaD
Irbesartan—AGTR1—GPCR ligand binding—AGT—dilated cardiomyopathy	7.71e-05	0.000785	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—RAF1—dilated cardiomyopathy	7.64e-05	0.000777	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	7.49e-05	0.000762	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—CXCR3—dilated cardiomyopathy	7.49e-05	0.000762	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CXCL2—dilated cardiomyopathy	7.32e-05	0.000744	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AGTR2—dilated cardiomyopathy	7.32e-05	0.000744	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—ANKRD1—dilated cardiomyopathy	7.26e-05	0.000739	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—ADRB1—dilated cardiomyopathy	7.25e-05	0.000738	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—ANKRD1—dilated cardiomyopathy	7.2e-05	0.000733	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—AGTR1—dilated cardiomyopathy	7.17e-05	0.000729	CbGpPWpGaD
Irbesartan—JUN—Direct p53 effectors—EGFR—dilated cardiomyopathy	6.86e-05	0.000697	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—TAZ—dilated cardiomyopathy	6.83e-05	0.000695	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—ADRB2—dilated cardiomyopathy	6.8e-05	0.000692	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—CXCR3—dilated cardiomyopathy	6.8e-05	0.000692	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—TAZ—dilated cardiomyopathy	6.77e-05	0.000689	CbGpPWpGaD
Irbesartan—PTGS1—Selenium Micronutrient Network—TNF—dilated cardiomyopathy	6.61e-05	0.000672	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—ADRB1—dilated cardiomyopathy	6.59e-05	0.00067	CbGpPWpGaD
Irbesartan—JUN—Regulation of toll-like receptor signaling pathway—TNF—dilated cardiomyopathy	6.57e-05	0.000668	CbGpPWpGaD
Irbesartan—AGTR1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—dilated cardiomyopathy	6.51e-05	0.000662	CbGpPWpGaD
Irbesartan—JUN—Integrated Breast Cancer Pathway—EGFR—dilated cardiomyopathy	6.45e-05	0.000656	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—PSEN2—dilated cardiomyopathy	6.2e-05	0.000631	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—SDHA—dilated cardiomyopathy	6.12e-05	0.000623	CbGpPWpGaD
Irbesartan—JUN—EGF/EGFR Signaling Pathway—EGFR—dilated cardiomyopathy	6.1e-05	0.00062	CbGpPWpGaD
Irbesartan—JUN—SIDS Susceptibility Pathways—TNF—dilated cardiomyopathy	5.99e-05	0.000609	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—EGFR—dilated cardiomyopathy	5.93e-05	0.000603	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—ADRB2—dilated cardiomyopathy	5.88e-05	0.000598	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—RAC1—dilated cardiomyopathy	5.81e-05	0.000591	CbGpPWpGaD
Irbesartan—JUN—Fc epsilon receptor (FCERI) signaling—EGFR—dilated cardiomyopathy	5.68e-05	0.000578	CbGpPWpGaD
Irbesartan—JUN—MAPK Signaling Pathway—TNF—dilated cardiomyopathy	5.64e-05	0.000574	CbGpPWpGaD
Irbesartan—EDNRA—GPCR downstream signaling—AGT—dilated cardiomyopathy	5.56e-05	0.000565	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AGTR2—dilated cardiomyopathy	5.51e-05	0.00056	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CXCL2—dilated cardiomyopathy	5.51e-05	0.00056	CbGpPWpGaD
Irbesartan—JUN—Focal Adhesion—EGFR—dilated cardiomyopathy	5.37e-05	0.000546	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—EGFR—dilated cardiomyopathy	5.35e-05	0.000544	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—ADRB2—dilated cardiomyopathy	5.34e-05	0.000543	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—RAC1—dilated cardiomyopathy	5.28e-05	0.000537	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—dilated cardiomyopathy	5.24e-05	0.000533	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—dilated cardiomyopathy	5.24e-05	0.000533	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—CD36—dilated cardiomyopathy	5.15e-05	0.000524	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—CXCR3—dilated cardiomyopathy	5.12e-05	0.000521	CbGpPWpGaD
Irbesartan—JUN—Integrated Pancreatic Cancer Pathway—TNF—dilated cardiomyopathy	5.09e-05	0.000518	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—AGT—dilated cardiomyopathy	5.05e-05	0.000513	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—dilated cardiomyopathy	4.99e-05	0.000507	CbGpPWpGaD
Irbesartan—CYP1A2—Aryl Hydrocarbon Receptor—TNF—dilated cardiomyopathy	4.99e-05	0.000507	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ADRB1—dilated cardiomyopathy	4.96e-05	0.000504	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—PSEN2—dilated cardiomyopathy	4.87e-05	0.000495	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—RAC1—dilated cardiomyopathy	4.86e-05	0.000494	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—ANKRD1—dilated cardiomyopathy	4.65e-05	0.000473	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—RAC1—dilated cardiomyopathy	4.56e-05	0.000464	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—TAZ—dilated cardiomyopathy	4.37e-05	0.000445	CbGpPWpGaD
Irbesartan—AGTR1—GPCR downstream signaling—AGT—dilated cardiomyopathy	4.36e-05	0.000443	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CXCL2—dilated cardiomyopathy	4.32e-05	0.00044	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AGTR2—dilated cardiomyopathy	4.32e-05	0.00044	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AGTR1—dilated cardiomyopathy	4.24e-05	0.000431	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—RAC1—dilated cardiomyopathy	4.14e-05	0.000421	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—ADRB2—dilated cardiomyopathy	4.02e-05	0.000409	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—CXCR3—dilated cardiomyopathy	4.02e-05	0.000409	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—AGT—dilated cardiomyopathy	3.96e-05	0.000403	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—SDHA—dilated cardiomyopathy	3.96e-05	0.000402	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ADRB1—dilated cardiomyopathy	3.89e-05	0.000396	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—ANKRD1—dilated cardiomyopathy	3.82e-05	0.000388	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—ANKRD1—dilated cardiomyopathy	3.79e-05	0.000385	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	3.74e-05	0.00038	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	3.64e-05	0.00037	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—PSEN2—dilated cardiomyopathy	3.64e-05	0.00037	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—TAZ—dilated cardiomyopathy	3.59e-05	0.000365	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—TAZ—dilated cardiomyopathy	3.56e-05	0.000362	CbGpPWpGaD
Irbesartan—JUN—Immune System—ITGB1—dilated cardiomyopathy	3.52e-05	0.000358	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—RAF1—dilated cardiomyopathy	3.5e-05	0.000356	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	3.45e-05	0.000351	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	3.28e-05	0.000333	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—SDHA—dilated cardiomyopathy	3.25e-05	0.00033	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—ANKRD1—dilated cardiomyopathy	3.24e-05	0.000329	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AGTR2—dilated cardiomyopathy	3.23e-05	0.000328	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CXCL2—dilated cardiomyopathy	3.23e-05	0.000328	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—RAF1—dilated cardiomyopathy	3.22e-05	0.000328	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—SDHA—dilated cardiomyopathy	3.22e-05	0.000327	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—ADRB2—dilated cardiomyopathy	3.15e-05	0.000321	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—RAC1—dilated cardiomyopathy	3.12e-05	0.000317	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—TAZ—dilated cardiomyopathy	3.04e-05	0.000309	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—CXCR3—dilated cardiomyopathy	3e-05	0.000305	CbGpPWpGaD
Irbesartan—JUN—Immune System—CD36—dilated cardiomyopathy	3e-05	0.000305	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—AGT—dilated cardiomyopathy	2.98e-05	0.000303	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—GPX1—dilated cardiomyopathy	2.95e-05	0.0003	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ADRB1—dilated cardiomyopathy	2.91e-05	0.000296	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—CD36—dilated cardiomyopathy	2.88e-05	0.000293	CbGpPWpGaD
Irbesartan—JUN—Immune System—RAC1—dilated cardiomyopathy	2.83e-05	0.000288	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—SDHA—dilated cardiomyopathy	2.75e-05	0.00028	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—RAF1—dilated cardiomyopathy	2.75e-05	0.000279	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.71e-05	0.000276	CbGpPWpGaD
Irbesartan—UGT1A3—Metabolism—AGT—dilated cardiomyopathy	2.59e-05	0.000263	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—ANKRD1—dilated cardiomyopathy	2.5e-05	0.000254	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AGTR1—dilated cardiomyopathy	2.48e-05	0.000253	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—RAC1—dilated cardiomyopathy	2.45e-05	0.000249	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	2.41e-05	0.000245	CbGpPWpGaD
Irbesartan—EDNRA—Signaling by GPCR—EGFR—dilated cardiomyopathy	2.4e-05	0.000244	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—ADRB2—dilated cardiomyopathy	2.36e-05	0.00024	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	2.35e-05	0.000239	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—TAZ—dilated cardiomyopathy	2.35e-05	0.000239	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—AGT—dilated cardiomyopathy	2.34e-05	0.000238	CbGpPWpGaD
Irbesartan—JUN—Innate Immune System—EGFR—dilated cardiomyopathy	2.21e-05	0.000225	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—SDHA—dilated cardiomyopathy	2.12e-05	0.000216	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	2.12e-05	0.000215	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—RAF1—dilated cardiomyopathy	2.07e-05	0.00021	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RPS6KB1—dilated cardiomyopathy	2.02e-05	0.000206	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.96e-05	0.0002	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.91e-05	0.000195	CbGpPWpGaD
Irbesartan—AGTR1—Signaling by GPCR—EGFR—dilated cardiomyopathy	1.88e-05	0.000192	CbGpPWpGaD
Irbesartan—JUN—Immune System—RAF1—dilated cardiomyopathy	1.88e-05	0.000191	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RAC1—dilated cardiomyopathy	1.83e-05	0.000186	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—AGT—dilated cardiomyopathy	1.75e-05	0.000178	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.72e-05	0.000175	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—dilated cardiomyopathy	1.68e-05	0.000171	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—GPX1—dilated cardiomyopathy	1.66e-05	0.000169	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—CD36—dilated cardiomyopathy	1.63e-05	0.000166	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—RAF1—dilated cardiomyopathy	1.62e-05	0.000165	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—CD36—dilated cardiomyopathy	1.62e-05	0.000165	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism of lipids and lipoproteins—AGT—dilated cardiomyopathy	1.47e-05	0.00015	CbGpPWpGaD
Irbesartan—PTGS1—Metabolism—AGT—dilated cardiomyopathy	1.46e-05	0.000148	CbGpPWpGaD
Irbesartan—EDNRA—Signaling Pathways—EGFR—dilated cardiomyopathy	1.42e-05	0.000144	CbGpPWpGaD
Irbesartan—JUN—Immune System—EGFR—dilated cardiomyopathy	1.29e-05	0.000131	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—RAF1—dilated cardiomyopathy	1.21e-05	0.000123	CbGpPWpGaD
Irbesartan—AGTR1—Signaling Pathways—EGFR—dilated cardiomyopathy	1.11e-05	0.000113	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—GPX1—dilated cardiomyopathy	1.07e-05	0.000109	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—CD36—dilated cardiomyopathy	1.05e-05	0.000106	CbGpPWpGaD
Irbesartan—CYP2C8—Metabolism—AGT—dilated cardiomyopathy	9.42e-06	9.58e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—GPX1—dilated cardiomyopathy	8.82e-06	8.97e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—GPX1—dilated cardiomyopathy	8.75e-06	8.89e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—CD36—dilated cardiomyopathy	8.59e-06	8.74e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—CD36—dilated cardiomyopathy	8.52e-06	8.66e-05	CbGpPWpGaD
Irbesartan—JUN—Signaling Pathways—EGFR—dilated cardiomyopathy	8.32e-06	8.46e-05	CbGpPWpGaD
Irbesartan—CYP2D6—Metabolism—AGT—dilated cardiomyopathy	7.74e-06	7.87e-05	CbGpPWpGaD
Irbesartan—CYP2C9—Metabolism—AGT—dilated cardiomyopathy	7.67e-06	7.8e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—GPX1—dilated cardiomyopathy	7.47e-06	7.6e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—CD36—dilated cardiomyopathy	7.28e-06	7.4e-05	CbGpPWpGaD
Irbesartan—CYP1A2—Metabolism—AGT—dilated cardiomyopathy	6.55e-06	6.67e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—GPX1—dilated cardiomyopathy	5.77e-06	5.87e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—CD36—dilated cardiomyopathy	5.62e-06	5.71e-05	CbGpPWpGaD
Irbesartan—CYP3A4—Metabolism—AGT—dilated cardiomyopathy	5.06e-06	5.14e-05	CbGpPWpGaD
